Tumor‐Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti‐FGF23 Monoclonal Antibody
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.4280
Abstract: I n this issue of JBMR, Jan de Beur and colleagues (1) report the primary analysis and findings up to closure of their prospective, open-label, single-arm, phase 2 study (NCT02304367) to evaluate the safety and… read more here.
Keywords: treatment; tumor induced; tio; induced osteomalacia ... See more keywords
O117 Burosumab in the management of X-linked hypophosphataemia: a retrospective cohort study reviewing anthropometric and biochemical markers
Sign Up to like & getrecommendations! Published in 2023 at "British Journal of Surgery"
DOI: 10.1093/bjs/znad101.117
Abstract: Rickets is a bone disease caused by a defect in mineralization. When left untreated, it has lifelong Orthopaedic sequelae. Burosumab, an anti-fibroblast growth factor 23 monoclonal antibody, improves rickets severity, symptoms, and growth in children… read more here.
Keywords: phosphate; phosphate concentration; growth; burosumab ... See more keywords
Clinical practice guidelines for paediatric X‐linked hypophosphataemia in the era of burosumab
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Paediatrics and Child Health"
DOI: 10.1111/jpc.15976
Abstract: X‐linked hypophosphataemia (XLH), the most common inherited form of rickets, is caused by a PHEX gene mutation that leads to excessive serum levels of fibroblast growth factor 23 (FGF23). This leads to clinical manifestations such… read more here.
Keywords: era burosumab; burosumab; linked hypophosphataemia; clinical practice ... See more keywords
Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels
Sign Up to like & getrecommendations! Published in 2023 at "Archives of Disease in Childhood"
DOI: 10.1136/archdischild-2022-324962
Abstract: Background Burosumab, an antifibroblast growth factor 23 monoclonal antibody, improves rickets severity, symptoms and growth in children with X-linked hypophosphataemia (XLH) followed up to 64 weeks in clinical trials. International dosing guidance recommends targeting normal… read more here.
Keywords: phosphate; phosphate concentration; growth; burosumab ... See more keywords
Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.1004624
Abstract: Introduction X-linked hypophosphatemia (XLH) is the most prevalent type of heritable fibroblast growth factor 23 (FGF23)-related hypophosphatemic rickets. Recently, anti-FGF23 antibody, burosumab, has become clinically available. We herein report a patient with adult XLH and… read more here.
Keywords: burosumab; tertiary hyperparathyroidism; adult xlh; treatment ... See more keywords
Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.1034580
Abstract: Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab… read more here.
Keywords: burosumab linked; burosumab; burosumab treatment; children adolescents ... See more keywords